Raltegravir

• Description :

  Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.

• CAS Number :

  [518048-05-0]

• Product Name Alternative :

  MK-0518

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H320, H335

• Target :

  HIV; HIV Integrase

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/raltegravir.html

• Purity :

  99.93

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(C(O)=C(C(NCC1=CC=C(C=C1)F)=O)N=C2C(C)(C)NC(C3=NN=C(C)O3)=O)N2C

• Molecular Formula :

  C20H21FN6O5

• Molecular Weight :

  444.42

• Precautions :

  H302, H315, H320, H335

• References & Citations :

  [1]Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107 (46) : p. 20057-62.|[2]Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48 (7) :931-9|[3]Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56 (6) :3020-6|[4]Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572) . Mol Pharmacol. 2011 Oct;80 (4) :565-72.|[5]Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21.|[6]Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12 (4) :682-692.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  HIV-1; HIV-2

• Citation 01 :

  Bioorg Med Chem. 2019 Sep 1;27 (17) :3836-3845. |bioRxiv. 2025 Aug 14:2025.08.14.670267.|Cell Rep Med. 2025 Aug 20:102311.|Clin Drug Investig. 2019 Mar;39 (3) :285-299.|J Infect Dis. 2022 Nov 28;226 (11) :1992-2001.|J Mol Biol. 2022 Apr 15;434 (7) :167507.|J Neuroimmune Pharmacol. 2017 Dec;12 (4) :682-692.|J Virol. 2017 Jan 18;91 (3) . pii: e02152-16.|Life Sci. 2022 Nov 1:308:120948.|Mol Divers. 2025 Nov 12.|Molecules. 2022 Dec 12;27 (24) :8829.|Open Forum Infect Dis. 2024 Nov 29;12 (1) :ofae705.|PeerJ Physical Chemistry. 2019, 1:e6.|Pharmaceuticals (Basel) . 2023 Aug 8;16 (8) :1118.|Phytomedicine. 2016 Nov 15;23 (12) :1383-1391. |Phytomedicine. 2025 Jun:141:156667.|Preprints. 2024 Apr 23.|Preprints. 2024 Feb 19.|SSRN. 2023 Mar 30.|Virol Sin. 2023 Jun;38 (3) :448-458.|Virology. 2023 Aug:585:205-214.|Viruses. 2021 Jan 18;13 (1) :131.|Viruses. 2024 Oct 13;16 (10) :1607.|Plant Biosyst. 2018, 1-8.|PLoS One. 2018 Mar 30;13 (3) :e0195168.